Compare Stocks: KALV, AMRX, DFTX, and INDV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$17.44 -2.4%	$17.76	$9.44 ▼ $19.26	$5.57B	1.24	1.72 million shs	1.43 million shs
DFTX Definium Therapeutics	$38.09 +0.2%	$43.70	$8.77 ▼ $49.70	$5.12B	2.23	2.22 million shs	1.13 million shs
INDV Indivior	$34.94 +0.3%	$38.76	$22.22 ▼ $42.81	$4.12B	0.82	2.04 million shs	1.02 million shs
KALV KalVista Pharmaceuticals	$27.00	$26.90	$9.83 ▼ $27.00	$1.44B	-0.12	3.07 million shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	-2.41%	-0.57%	-5.53%	+26.84%	+82.81%
DFTX Definium Therapeutics	+0.24%	-7.05%	-14.19%	+61.74%	+320.42%
INDV Indivior	+0.32%	+0.20%	-9.79%	-7.12%	+41.63%
KALV KalVista Pharmaceuticals	0.00%	0.00%	0.00%	+0.19%	+90.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$17.44 -2.4%	$17.76	$9.44 ▼ $19.26	$5.57B	1.24	1.72 million shs	1.43 million shs
DFTX Definium Therapeutics	$38.09 +0.2%	$43.70	$8.77 ▼ $49.70	$5.12B	2.23	2.22 million shs	1.13 million shs
INDV Indivior	$34.94 +0.3%	$38.76	$22.22 ▼ $42.81	$4.12B	0.82	2.04 million shs	1.02 million shs
KALV KalVista Pharmaceuticals	$27.00	$26.90	$9.83 ▼ $27.00	$1.44B	-0.12	3.07 million shs	N/A

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	-2.41%	-0.57%	-5.53%	+26.84%	+82.81%
DFTX Definium Therapeutics	+0.24%	-7.05%	-14.19%	+61.74%	+320.42%
INDV Indivior	+0.32%	+0.20%	-9.79%	-7.12%	+41.63%
KALV KalVista Pharmaceuticals	0.00%	0.00%	0.00%	+0.19%	+90.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	3.13	Buy	$19.00	8.94% Upside
DFTX Definium Therapeutics	3.00	Buy	$63.00	65.40% Upside
INDV Indivior	2.71	Moderate Buy	$45.17	29.27% Upside
KALV KalVista Pharmaceuticals	2.22	Hold	$33.25	23.15% Upside

Current Analyst Ratings Breakdown

Latest KALV, AMRX, DFTX, and INDV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	AMRX Amneal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/26/2026	AMRX Amneal Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$22.00
8/21/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/18/2026	DFTX Definium Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/14/2026	DFTX Definium Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $55.00
8/13/2026	DFTX Definium Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$58.00 ➝ $64.00
8/13/2026	DFTX Definium Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$74.00 ➝ $90.00
8/13/2026	DFTX Definium Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$57.00 ➝ $66.00
8/13/2026	DFTX Definium Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$68.00 ➝ $72.00
8/13/2026	DFTX Definium Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$57.00 ➝ $75.00
8/12/2026	AMRX Amneal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	1.84	$1.52 per share	11.44	$0.10 per share	174.40
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	$6.84 per share	N/A
INDV Indivior	$1.24B	3.33	$2.73 per share	12.81	($1.76) per share	-19.85
KALV KalVista Pharmaceuticals	$1.43M	1,008.07	N/A	N/A	$2.71 per share	9.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	35.59	16.15	N/A	5.05%	-584.46%	7.78%	N/A
DFTX Definium Therapeutics	-$183.79M	-$3.43	N/A	N/A	N/A	N/A	-84.01%	-63.66%	N/A
INDV Indivior	$210M	$2.79	12.52	9.12	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
KALV KalVista Pharmaceuticals	-$109.52M	-$3.46	N/A	36.00	N/A	N/A	-341.44%	-111.94%	N/A

Latest KALV, AMRX, DFTX, and INDV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	DFTX Definium Therapeutics	-$0.55	-$1.44	-$0.89	-$1.44	N/A	N/A
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million
6/30/2026	Q2 2026	INDV Indivior	N/A	$5.75	N/A	$4.90	N/A	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
DFTX Definium Therapeutics	0.04	6.95	6.95
INDV Indivior	N/A	0.84	0.66
KALV KalVista Pharmaceuticals	8.18	5.17	5.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
DFTX Definium Therapeutics	27.91%
INDV Indivior	60.33%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
DFTX Definium Therapeutics	2.40%
INDV Indivior	0.74%
KALV KalVista Pharmaceuticals	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
DFTX Definium Therapeutics	40	134.37 million	131.14 million	Optionable
INDV Indivior	1,051	118.01 million	117.14 million	Not Optionable
KALV KalVista Pharmaceuticals	100	53.24 million	50.95 million	Optionable

KALV, AMRX, DFTX, and INDV Headlines

Recent News About These Companies

DRI Healthcare Trust Collects $178M for Ekterly Royalty Exit

August 11, 2026 | marketwatch.com

DRI Healthcare Exercises Put Option for $178M Payout

July 10, 2026 | marketwatch.com

A Framingham biotech just became a $1.9B Italian acquisition. Here’s the drug behind it

June 16, 2026 | masslive.comM

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

June 11, 2026 | businesswire.com

KalVista’s Sebetralstat Extension Study Completion Sets Up Key Catalyst for KALV Investors

June 5, 2026 | tipranks.com

KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?

June 4, 2026 | zacks.com

KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000

May 31, 2026 | fool.com

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

May 28, 2026 | businesswire.com

Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 1,489 Shares of Stock

May 28, 2026 | insidertrades.com

KalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 1,489 Shares

May 27, 2026 | insidertrades.com

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

May 19, 2026 | businesswire.com

Merger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity Risks

May 16, 2026 | tipranks.com

KalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47

May 15, 2026 | msn.com

Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 3,322 Shares of Stock

May 14, 2026 | insidertrades.com

A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains

May 10, 2026 | finance.yahoo.com

Italy's Angelini to buy Catalyst Pharma for $4.1 billion in US market expansion

May 7, 2026 | msn.com

HC Wainwright & Co. downgrades KalVista Pharmaceuticals (KALV)

May 2, 2026 | msn.com

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

May 1, 2026 | businesswire.com

KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

May 1, 2026 | tmcnet.com

Chiesi widens rare disease portfolio with $1.9bn KalVista buyout

May 1, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, AMRX, DFTX, and INDV Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$17.44 -0.43 (-2.41%)

As of 09/4/2026 04:00 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Definium Therapeutics NASDAQ:DFTX

$38.09 +0.09 (+0.24%)

As of 09/4/2026 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Indivior NASDAQ:INDV

$34.94 +0.11 (+0.32%)

As of 09/4/2026 04:00 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

KalVista Pharmaceuticals NASDAQ:KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KALV, AMRX, DFTX, and INDV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KALV, AMRX, DFTX, and INDV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KALV, AMRX, DFTX, and INDV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, AMRX, DFTX, and INDV Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Definium Therapeutics NASDAQ:DFTX

Indivior NASDAQ:INDV

KalVista Pharmaceuticals NASDAQ:KALV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KALV, AMRX, DFTX, and INDV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KALV, AMRX, DFTX, and INDV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KALV, AMRX, DFTX, and INDV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, AMRX, DFTX, and INDV Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Definium Therapeutics NASDAQ:DFTX

Indivior NASDAQ:INDV

KalVista Pharmaceuticals NASDAQ:KALV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools